Chen Schor, Adicet Bio CEO
June 6, 2022 11:22 AM EDTUpdated 01:38 PM
R&D

#AS­CO22: Ear­ly stock win­ner Adicet re­ports CRs for their off-the-shelf gam­ma delta CAR-T

Paul Schloesser

Associate Editor

Adicet is get­ting cen­ter-ring at­ten­tion to­day for its pos­i­tive cut of the ear­ly da­ta for their off-the-shelf gam­ma delta T cell play­er.

At the da­ta …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times